Affymax, Inc. announced that it will retain a bank to evaluate strategic alternatives for the organization, including the sale of the company or its assets, or a corporate merger. Affymax is considering all possible alternatives, including further restructuring activities, wind-down of operations or even bankruptcy proceedings. Affymax announced that it will reduce its workforce by 75% as part of a plan to focus the company's resources on the ongoing investigation of reported hypersensitivity reactions in patients receiving OMONTYS Injection.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0008 USD | +6.67% | 0.00% | +33.33% |
1st Jan change | Capi. | |
---|---|---|
+33.33% | 55.87T | |
+34.83% | 5.08TCr | |
+0.61% | 4.28TCr | |
+49.62% | 4.2TCr | |
-4.96% | 2.95TCr | |
+10.80% | 2.61TCr | |
-21.56% | 1.91TCr | |
+8.63% | 1.31TCr | |
+26.98% | 1.22TCr | |
+24.40% | 1.21TCr |
- Stock Market
- Equities
- AFFY Stock
- News Affymax, Inc.
- Affymax Seeks Strategic Alternatives